124276-95-5

Usage

Uses

Used in Organic Synthesis:
1-(3-Bromophenyl)cyclopropanecarboxylic acid serves as a crucial intermediate in organic synthesis, where it is used as a building block for the preparation of various complex organic molecules. Its unique structural features facilitate the formation of new chemical entities with potential applications in different industries.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-(3-Bromophenyl)cyclopropanecarboxylic acid is employed as a precursor for the synthesis of pharmaceutical compounds. Its presence in the molecular structure can influence the pharmacological properties of the resulting compounds, making it a valuable component in drug discovery and development processes.
Used in Drug Discovery and Development:
1-(3-Bromophenyl)cyclopropanecarboxylic acid is being studied for its potential biological activities, which may contribute to its use in drug discovery and development. 1-(3-Bromophenyl)cyclopropanecarboxylic acid's unique structural elements, including the bromine atom and the cyclopropane ring, are believed to play a role in its interactions with biological targets, offering new avenues for therapeutic intervention.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, 1-(3-Bromophenyl)cyclopropanecarboxylic acid is utilized as a key component in the development of new drugs. Its unique properties and potential biological activities make it a promising candidate for the treatment of various diseases and conditions, contributing to the advancement of medical therapies.

InChI:InChI=1/C10H9BrO2/c11-8-3-1-2-7(6-8)10(4-5-10)9(12)13/h1-3,6H,4-5H2,(H,12,13)

Upstream product

• 597563-13-8 1-(3-bromophenyl)cyclopropanecarboxamide 
• 31938-07-5 (3-bromophenyl)acetonitrile 
• 124276-83-1 1-(3-bromophenyl)cyclopropane-1-carbonitrile 

Downstream Products

• 597563-14-9 C₁₀H₈BrClO 
• 749928-59-4 methyl 1-(3-bromophenyl)cyclopropane-1-carboxylate 
• 597563-13-8 1-(3-bromophenyl)cyclopropanecarboxamide 
• 1359981-61-5 1-(3-bromophenyl)cyclopropanecarboxylic acid ethyl ester 
• 1252638-94-0 (4R)-1-{[1-(3-bromophenyl)cyclopropyl]carbonyl}-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1268444-74-1 (4R)-1-{[1-(3-bromophenyl)cyclopropyl]carbonyl}-4-[(2-chlorophenyl)sulfonyl]-N-(1-cyanocyclopropyl)-L-prolinamide 
• 597563-17-2 tert-butyl N-[1-(3-bromophenyl)cyclopropyl]carbamate 
• 546115-65-5 1-(3-bromophenyl)cyclopropan-1-amine 

Relevant academic research and scientific papers

Preparation method of arylcyclopropane compound

The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS

The invention includes procedures for stereoselective β-arylation of carboxylic acids having a β-carbon atom. For example, stereoselective arylation procedures include the following reactions: (I)

A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES

The present invention relates to a process for the manufacturing of 1-aryl-1-trifluoromethylcyclopropanes, which serve as intermediates for the manufacturing of calcium T channel blockers of the general formula (A) which are described in WO 2015/186056.

Pd(II)-Catalyzed Enantioselective C(sp3)-H Arylation of Free Carboxylic Acids

A monoprotected aminoethyl amine chiral ligand based on an ethylenediamine backbone was developed to achieve Pd-catalyzed enantioselective C(sp3)-H arylation of cyclopropanecarboxylic and 2-aminoisobutyric acids without using exogenous directing groups. This new chiral catalyst affords new disconnection for preparing diverse chiral carboxylic acids from simple starting materials that are complementary to the various ring forming approaches.

NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON I B KINASE

Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R1 represents a hydrogen atom, a lower alkyl group, an aryl group, a hydroxy group, or the like; R2 represents a halogen atom, a lower alkyl group, a lower alkenyl group, a lower alkynyl group, or the like; and m represents 0, 1, 2, or the like.

CATHEPSIN CYSTEINE PROTEASE INHIBITORS

This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

PROCESS FOR PREPARING 5-(1, 3-OXAZOL-2-YL) BENZOIC ACID DERIVATIVES

Disclosed are compounds of formula III and a process to prepare a compound of formula III wherein R1, R2, R3 and R6 are defined herein, using a zinc chloride/optionally substituted oxazole adduct and an compound